Uenaka K - Search Results

1

A phase I dose-escalation study of LY2875358, a bivalent MET antibody, given as monotherapy or in combination with erlotinib or gefitinib in Japanese patients with advanced malignancies.

Yoh K, Doi T, Ohmatsu H, Kojima T, Takahashi H, Zenke Y, Wacheck V, Enatsu S, Nakamura T, Turner K, Uenaka K. Yoh K, et al. Among authors: uenaka k. Invest New Drugs. 2016 Oct;34(5):584-95. doi: 10.1007/s10637-016-0370-7. Epub 2016 Sep 1. Invest New Drugs. 2016. PMID: 27422720 Free PMC article. Clinical Trial.

2

Phase I study of LY2603618, a CHK1 inhibitor, in combination with gemcitabine in Japanese patients with solid tumors.

Doi T, Yoshino T, Shitara K, Matsubara N, Fuse N, Naito Y, Uenaka K, Nakamura T, Hynes SM, Lin AB. Doi T, et al. Among authors: uenaka k. Anticancer Drugs. 2015 Nov;26(10):1043-53. doi: 10.1097/CAD.0000000000000278. Anticancer Drugs. 2015. PMID: 26288133 Clinical Trial.

3

Dose-escalation study of tabalumab with bortezomib and dexamethasone in Japanese patients with multiple myeloma.

Iida S, Ogiya D, Abe Y, Taniwaki M, Asou H, Maeda K, Uenaka K, Nagaoka S, Ishiki T, Conti I, Tobinai K. Iida S, et al. Among authors: uenaka k. Cancer Sci. 2016 Sep;107(9):1281-9. doi: 10.1111/cas.13000. Epub 2016 Sep 1. Cancer Sci. 2016. PMID: 27350068 Free PMC article. Clinical Trial.

4

A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer.

Sakai D, Chung HC, Oh DY, Park SH, Kadowaki S, Kim YH, Tsuji A, Komatsu Y, Kang YK, Uenaka K, Wijayawardana SR, Wacheck V, Wang X, Yamamura A, Doi T. Sakai D, et al. Among authors: uenaka k. Cancer Chemother Pharmacol. 2017 Dec;80(6):1197-1207. doi: 10.1007/s00280-017-3445-z. Epub 2017 Oct 25. Cancer Chemother Pharmacol. 2017. PMID: 29071414 Free PMC article. Clinical Trial.

5

Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus.

Kothare PA, Linnebjerg H, Isaka Y, Uenaka K, Yamamura A, Yeo KP, de la Peña A, Teng CH, Mace K, Fineman M, Shigeta H, Sakata Y, Irie S. Kothare PA, et al. Among authors: uenaka k. J Clin Pharmacol. 2008 Dec;48(12):1389-99. doi: 10.1177/0091270008323750. J Clin Pharmacol. 2008. PMID: 19047364 Clinical Trial.

6

Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors.

Tanioka M, Nokihara H, Yamamoto N, Yamada Y, Yamada K, Goto Y, Fujimoto T, Sekiguchi R, Uenaka K, Callies S, Tamura T. Tanioka M, et al. Among authors: uenaka k. Cancer Chemother Pharmacol. 2011 Aug;68(2):505-11. doi: 10.1007/s00280-010-1506-7. Epub 2010 Nov 16. Cancer Chemother Pharmacol. 2011. PMID: 21079959 Clinical Trial.

7

Effects of teriparatide in Japanese and non-Japanese populations: bridging findings on pharmacokinetics and efficacy.

Tsujimoto M, Uenaka K, Iwata A, Higashiuchi Y, Sowa H. Tsujimoto M, et al. Among authors: uenaka k. J Bone Miner Metab. 2012 May;30(3):326-37. doi: 10.1007/s00774-011-0314-4. Epub 2011 Sep 21. J Bone Miner Metab. 2012. PMID: 21938381 Clinical Trial.

8

Comparison of pharmacokinetics, pharmacodynamics, safety, and tolerability of the amyloid β monoclonal antibody solanezumab in Japanese and white patients with mild to moderate alzheimer disease.

Uenaka K, Nakano M, Willis BA, Friedrich S, Ferguson-Sells L, Dean RA, Ieiri I, Siemers ER. Uenaka K, et al. Clin Neuropharmacol. 2012 Jan-Feb;35(1):25-9. doi: 10.1097/WNF.0b013e31823a13d3. Clin Neuropharmacol. 2012. PMID: 22134132 Clinical Trial.

9

Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors.

Yamamoto N, Nokihara H, Yamada Y, Uenaka K, Sekiguchi R, Makiuchi T, Slapak CA, Benhadji KA, Tamura T. Yamamoto N, et al. Among authors: uenaka k. Cancer Chemother Pharmacol. 2013 Jun;71(6):1645-55. doi: 10.1007/s00280-013-2165-2. Epub 2013 Apr 25. Cancer Chemother Pharmacol. 2013. PMID: 23616084 Clinical Trial.

10

CPT-11: population pharmacokinetic model and estimation of pharmacokinetics using the Bayesian method in patients with lung cancer.

Yamamoto N, Tamura T, Karato A, Uenaka K, Eguchi K, Shinkai T, Ohe Y, Oshita F, Arioka H, Nakashima H, et al. Yamamoto N, et al. Among authors: uenaka k. Jpn J Cancer Res. 1994 Sep;85(9):972-7. doi: 10.1111/j.1349-7006.1994.tb02977.x. Jpn J Cancer Res. 1994. PMID: 7961128 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

23 results

Search Page

Filters